Glucagon-like Peptide-1: A focus on neurodegenerative diseases
Chen Z, Zheng Z, Huang J, Lai Z, Fan B
Kherad, Meyrin (Mdecine interne gnrale)
As such, we conclude that rs10305420 is probably the causal variant
legal help when you need it most
Novo Nordisk reined in its growth forecasts for the year in its second-quarter financial results update, blaming "persistent use of compounded GLP-1s, slower-than-expected market expansion, and competition." Compounding of semaglutide should have come to a halt in the US since the drug was removed from the FDA list of medicines in short supply, but various companies continue to provide compounded GLP-1s under a loophole that allows the sale of 'personalised' formulations